TC Medical(SH:600763) Sou Hu Cai Jing·2026-01-19 11:42Core Viewpoint - Tongce Medical (600763) shows a steady performance with a slight increase in stock price and positive financial results for the third quarter of 2025, indicating potential growth in the medical services sector [1][2]. Financial Performance - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56% [2]. - The net profit attributable to shareholders reached 514 million yuan, up 3.16% year-on-year, while the net profit excluding non-recurring items was 509 million yuan, reflecting a 3.09% increase [2]. - In Q3 2025 alone, the company achieved a single-quarter revenue of 842 million yuan, a 2.34% increase year-on-year, and a net profit of 192 million yuan, up 2.31% year-on-year [2]. - The company's debt ratio stands at 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan, resulting in a gross profit margin of 41.69% [2]. Market Activity - As of January 19, 2026, Tongce Medical's stock closed at 45.1 yuan, marking a 0.6% increase with a turnover rate of 3.42% and a trading volume of 153,100 hands, amounting to a total transaction value of 694 million yuan [1]. - The net inflow of main funds was 33.53 million yuan, accounting for 4.83% of the total transaction value, while retail investors experienced a net outflow of 53.02 million yuan, representing 7.64% of the total transaction value [1]. Analyst Ratings - Over the past 90 days, seven institutions have provided ratings for Tongce Medical, with four giving a "buy" rating and three an "increase" rating [2]. - The average target price set by institutions in the last 90 days is 5.288 billion yuan [2].